Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.

Targeted Oncology
Sandrine FaivreEric Raymond

Abstract

Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tumor lesions. When exposed to vascular endothelial growth factor (VEGFR) inhibitors such as sunitinib, target lesions display few if any variation in tumor size, but rather detectable modifications in tumor density. In several patients treated with targeted therapy, a significant decrease of tumor density at first tumor evaluation can be detected as compared to baseline. Consistently, the two randomized trials leading to approval of sunitinib and everolimus in pancreatic neuroendocrine tumors report objective response rate below 10%, emphasizing that Response Evaluation Criteria in Solid Tumors (RECIST), that focus only on the largest diameters of target lesions, may be insufficient to capture the full benefit of targeted therapies. Alternative criteria, such as those developed by Choi et al., consider both the size and the density of the tumor as parameters for response evaluation. Choi criteria have been recently ...Continue Reading

References

Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clarisse DromainEric Baudin
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Dec 6, 2005·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·M RodallecY Menu
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert S BenjaminChuslip Charnsangavej
Aug 11, 2007·Nature Reviews. Drug Discovery·Sandrine FaivreEric Raymond
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jan 13, 2009·Cancer Treatment Reviews·I M E DesarW T A van der Graaf
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew X ZhuRakesh K Jain
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine J FaivreEric Raymond
Feb 23, 2010·Seminars in Liver Disease·Riccardo Lencioni, Josep M Llovet
Nov 26, 2010·Endocrinology and Metabolism Clinics of North America·Sandrine FaivreEric Raymond
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
May 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sandrine FaivreEric Raymond

❮ Previous
Next ❯

Citations

Oct 23, 2012·Cancer Metastasis Reviews·Cindy NeuzilletEric Raymond
Aug 25, 2012·Targeted Oncology·Eric RaymondSandrine Faivre
Mar 15, 2016·Best Practice & Research. Clinical Endocrinology & Metabolism·Tobias BaumannDamian Wild
Oct 5, 2015·Cancer Metastasis Reviews·Rocio Garcia-CarboneroUNKNOWN Spanish Cooperative Group of Neuroendocrine Tumors (GETNE)
Sep 5, 2013·Therapeutic Advances in Gastroenterology·Aaron I Vinik, Eric Raymond
May 17, 2018·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·X Merino-CasabielJ Capdevila
Nov 12, 2014·Molecular Medicine Reports·Lian Tao LiJun Nian Zheng
Jun 22, 2017·Targeted Oncology·Diana MartinsUNKNOWN IEO ENETS Center of Excellence for GEP NETs
Dec 19, 2018·Drugs·Aura D Herrera-MartínezRichard A Feelders
Feb 8, 2020·Current Medicinal Chemistry·Jorge Barriuso, Angela Lamarca
Dec 17, 2019·Advances in Medical Sciences·Anna MalczewskaIrvin M Modlin
Apr 20, 2021·Reviews in Endocrine & Metabolic Disorders·Marie-Pierre VulliermeLouis de Mestier
Oct 26, 2021·Journal of Neuroendocrinology·Clarisse DromainAnders Sundin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.